We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.
Health conditions and diseases that the clinical trial is designed to study and treat.
Triple Negative Breast Cancer (TNBC) is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2/neu gene. This makes it more challenging to treat.
Primary breast cancer refers to the initial occurrence of cancer in the breast tissue, which can be invasive or non-invasive. It is crucial to detect and treat it early for better outcomes.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.